CDDO-2P-Im

Research use only, not for human use.

CDDO-2P-Im, an analog of CDDO-Imidazolide, has a chemopreventive effect. It can reduce the size and severity of the lung tumors in the mouse lung cancer model.

CDDO-2P-Im, an analog of CDDO-Imidazolide, has a chemopreventive effect. It can reduce the size and severity of the lung tumors in the mouse lung cancer model.(In Vitro):In RAW264.7 cells, CDDO-2P-Im suppresses NO production (IC50: 5.8 nM). CDDO-2P-Im (100 nM) induces differentiation of U937 cells.(In Vivo):CDDO-2P-Im significantly elevates heme oxygenase-1 and quinone reductase mRNA and protein levels. In A/J mice, CDDO-2P-Im (50-200 mg/kg) decreases the number, size, and severity of tumors.

CDDO-2P-Im (100 nM; 4 days) induces differentiation of U937 cells at 100 nM.CDDO-2P-Im suppresses NO production in RAW264.7 cells with an IC50 of 5.8 nM. Apoptosis Analysis Cell Line:U937 cells Concentration:30 nM, 100 nM Incubation Time:4 days Result:Induced differentiation of U937 cells at 100 nM.

CDDO-2P-Im is more stable than CDDO-Im in pharmacokinetic studies.CDDO-2P-Im significantly elevates heme oxygenase-1 (HO-1) and quinone reductase (NQO1) mRNA and protein levels in various mouse tissues in vivo.CDDO-2P-Im (50-200 mg/kg; diet; for 16 weeks) decreases the number, the size and the severity of tumors in A/J mice. Animal Model:Seven week-old female A/J mice Dosage:50 mg/kg, 200 mg/kg Administration: Diet; for 16 weeks Result:Decreased the number, the size and the severity of tumors.

CDDO-2-P-Im

Others

Other Targets

——

——

——

1883650-96-1

618.822

C39H46N4O3

>98% (HPLC)

In Vitro:?DMSO : 200 mg/mL (323.20 mM)

[H][C@@]12CC(C)(C)CC[C@@]1(CC[C@]1(C)[C@]2([H])C(=O)C=C2[C@@]3(C)C=C(C#N)C(=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(=O)n1cnc(c1)-c1ccccn1

——

(-20℃)

With Ice Pack

≥ 2 years